Dositinib dose-escalation and expansion for advanced EGFR‑mutant non-small cell lung cancer

A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study on the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutations

This trial tests whether the EGFR inhibitor dositinib is safe and active for adults with locally advanced or metastatic non‑small cell lung cancer that has EGFR mutations.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 153 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Henan Genuine Biotech Co., Ltd. (Industry-sponsored)
• Drugs / interventions: gefitinib, erlotinib, icotinib, afatinib, Osimertinib, rociletinib, olmutinib, Mefatinib, Avitinib, chemotherapy, immunotherapy, radiation, Dositinib
• Locations: 5 sites (Beijing and 4 other locations)
• Trial ID: NCT07231068 on ClinicalTrials.gov

What this trial studies

This open‑label Phase I/II study uses a 3+3 dose escalation design to find tolerated doses of oral dositinib, followed by a dose‑expansion phase testing three selected dose levels for further safety, pharmacokinetics, and preliminary efficacy. Phase I will enroll patients who progressed on earlier EGFR‑TKIs (excluding third‑generation agents) to define the maximum tolerated dose and dose-limiting toxicities. Phase II will enroll participants with common sensitizing EGFR mutations (exon 19 deletion or L858R) to characterize response rates and tolerability at the chosen doses. All treatments are oral dositinib mesylate tablets and the study is conducted at major cancer centers in China.

Who should consider this trial

Good fit: Adults aged 18–75 with histologically or cytologically confirmed locally advanced (IIIB/IIIC) or metastatic (IV) NSCLC and documented sensitizing EGFR mutations are the intended participants, with dose‑escalation enrollment focused on those who progressed on earlier EGFR‑TKIs.

Not a fit: Patients without EGFR activating mutations, those previously treated with third‑generation EGFR TKIs, or those with poor organ function or contraindications to oral EGFR‑TKIs are unlikely to benefit from this study.

Why it matters

Potential benefit: If successful, dositinib could offer another oral targeted treatment option that controls tumor growth in EGFR‑mutant advanced NSCLC patients who have limited options after prior EGFR‑TKIs.

How similar studies have performed: Other EGFR tyrosine kinase inhibitors (like gefitinib, erlotinib, afatinib, and osimertinib) have shown clear benefit in EGFR‑mutant NSCLC, but dositinib itself is a new agent that has not yet been widely tested in this setting.

Eligibility criteria

Inclusion Criteria:

1. 18-75 years old (including 18 and 75 years old), male or female.
2. Histologically or cytologically confirmed patients with locally advanced NSCLC (stage IIIB / IIIc) or metastatic NSCLC (stage IV) who are unable to undergo radical surgery or radiotherapy (International Alliance against cancer, 8th Edition, 2017).
3. Locally advanced or metastatic NSCLC patients who have documentation of disease progression (with imaging evidence) while on previous continuous treatments with EGFR-TKI (such as gefitinib, erlotinib, icotinib, afatinib, etc., excluding the third-generation EGFR TKI drugs), or cannot tolerate the treatments for various reasons (only applicable to dose escalation part).
4. Patients with confirmed EGFR activating mutations that are sensitive to EGFR TKI at any time after initial diagnosis, in dose escalation part including G719X, exon 19 deletion, L858R, L861Q, in dose expansion part including exon 19 deletion and L858R.
5. No prior systemic antitumor therapy for locally advanced or metastatic NSCLC (patients who have received first-line chemotherapy but not TKI treatment can be enrolled). Patients who have undergone radical surgery, radical chemoradiotherapy or adjuvant treatment (chemotherapy, radiotherapy) for early-stage NSCLC and have experienced disease recurrence or metastasis later can be enrolled (only applicable to dose expansion part).
6. According to RECIST 1.1 response evaluation criteria in solid tumours, the patient has at least one imaging (CT, MRI) measurable or evaluable lesion, and accurate and repeatable measurement can be made at baseline, such as CT or MRI. In the dose expansion part, for the 160 mg and 200 mg dose groups, at least one measurable intracranial lesion is required in 20 to 30 patients with brain metastases. The long diameter of the lesion is more than or equal to 10 mm (if the lesion is a metastatic lymph node, the short diameter is more than or equal to 15 mm), and the lesion has not received radiotherapy or biopsy in the past (if the patient has only one target lesion and needs biopsy, the target lesion can be biopsied, and the time interval between the biopsy and the baseline assessment of the tumor in the screening period must be more than 2 weeks, and the target lesion still meets the definition in RECIST1.1 after biopsy). The same test method should be used in the follow-up evaluations.
7. Subjects with ECOG performance score of 0-1.
8. Patients whose life expectancy is at least 12 weeks.
9. Patients have adequate important organ functions during screening, including: a. The absolute neutrophil count (NEUT#) ≥ 1.5 x 10\^9/L without using hematopoietic stimulating factor within 14 days before the first administration; b. Platelet count ≥ 100 x 10\^9 / L without using hematopoietic stimulating factor or blood transfusion within 14 days before the first administration; c. Hemoglobin\>90g/L without using hematopoietic stimulating factor or blood transfusion within 14 days before the first administration; d. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN (ULN = upper limit of normal value) or ≤ 5 x ULN (patients with hepatic metastases); e. Total bilirubin ≤1.5 x ULN (ULN = upper limit of normal value) or ≤ 3 x ULN (patients with hepatic metastase); f. Coagulation function INR ≤ 1.5; g. Serum creatinine ≤ 1.5 x ULN (ULN = upper limit of normal value) and creatinine clearance rate (calculated by Cockcroft and Gault formula) ≥ 50ml / min.
10. Female subjects of childbearing age must confirm that the blood pregnancy test is negative and agree to use effective contraceptive measures during the use of the study drug and within 90 days after the last administration.

    In this program, female subjects of childbearing age are defined as sexually mature women. (1) No hysterectomy or bilateral oophorectomy is performed; (2) Natural amenorrhea doesn't last for 12 consecutive months (amenorrhea after cancer treatment does not exclude fertility) (i.e., menstruation occurred at any time in the previous 12 consecutive months); if the female partner of a male subject is fertile, the subject must agree to take adequate contraceptive measures from the first administration of the study treatment to 90 days after the last administration of the study treatment.
11. The subjects should give informed consent to the study and sign the informed consent form before the trial.

Exclusion Criteria:

1. Within 28 days before the first administration of the study treatment, the patients have used any chemotherapy drugs and / or immunotherapy drugs in the previous treatment regimen or clinical study; or have undergone major surgery (excluding vascular access establishment surgery) or received \> 30Gy within 28 days before the first administration of the study treatment. In addition to the local palliative radiotherapy for bone metastases, the patient have used an experimental drug or other anticancer drugs in the previous treatment regimen or clinical study within 14 days before the first administration of the study treatment, or stopped using other experimental drugs or anticancer drugs for less than 5 ×half-life (e.g., erlotinib less than 8 days, gefitinib less than 10 days, icotinib less than 2 days, afatinib less than 8 days).
2. Patients who have used the third generation EGFR TKI drugs (such as Osimertinib, rociletinib (co-1686), olmutinib (hm61713), asp8273, egf816, Mefatinib, Avitinib, etc.).
3. Patients who participated in other therapeutic clinical trials within one month before the first administration (patients who discontinue the experimental drug after more than five half-lives of the drug can be included in the study).
4. The patients are using (or cannot stop using) CYP3A4 strong inhibitor or inducer or Chinese herbal medicine with anti-tumor indications.
5. Patients who did not recover from the adverse events caused by previous anti-tumor therapy (recovered to ≤ 1 grade) (except for alopecia).
6. Patients with other malignant tumors within 5 years before the start of treatment (except for basal cell carcinoma or squamous cell carcinoma of the skin that is not melanoma, breast / cervical carcinoma in situ, superficial bladder carcinoma and other carcinoma in situ who have received radical treatment and no evidence of recurrence).
7. Any condition that affects the patients' swallowing of the drug and seriously affects the absorption or pharmacokinetic parameters of the investigational drug, including any kind of uncontrollable nausea and vomiting, chronic gastrointestinal diseases, inability of the patient to swallow the drug, history of gastrointestinal resection or surgery.
8. Patients with known organ transplantation.
9. Meet any of the following cardiac criteria: QTc interval \> 450ms in male and \> 470ms in female (QTc interval calculated by fridericia formula). All kinds of ECG morphological abnormalities with clinical significance, such as complete left bundle branch block, grade III block, grade II block, PR interval \> 250ms. Various factors that may increase the risk of QTc prolongation or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of immediate family members with long QT syndrome or unexplained sudden death before 40 years of age, and the use of any drug with known QT interval prolongation.
10. Past medical history: interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, active interstitial lung disease with clinical evidence; patients with active pulmonary tuberculosis (TB) who are receiving anti tuberculosis treatment or received anti tuberculosis treatment within one year before screening.
11. Pulmonary function test: forced expiratory volume in one second (FEV1) / forced vital capacity (FVC) \< 70%, FEV1% \< 30%, or DLCO% \< 40%.
12. Patients with spinal cord compression, or meningeal metastasis, or symptomatic and untreated brain metastasis (except those who are asymptomatic, stable, and do not need steroid therapy for more than 4 weeks before the start of study treatment).
13. The patients have a history of hypersensitivity to the active ingredients or inactive excipients of the study drug, drugs with chemical structure similar to the study drug or similar drugs, etc.).
14. At any time after the initial diagnosis, there are confirmed EGFR 20 exon insertion mutations.
15. Subjects are in the stage of acute infection and need medical treatment.
16. In the active stage of hepatitis B or hepatitis C: HBsAg positive and HBV DNA ≥ 10\^3 copies/mL or ≥ 200 IU/mL (HBV DNA is required when HBsAg is positive), HCVAb positive and HCV-RNA ≥ 10\^3 copies/mL (HCV-RNA is required when HCVAb is positive).
17. Subjects are HIV positive.
18. Subjects with a clear history of mental disorders and who have taken medication for treatment
19. Subjects have a history of drug abuse.
20. Pregnant or lactating women.
21. Women of childbearing age and fertile men can not take effective contraceptive measures during the period from signing the informed consent to 90 days after the last use of the study drug.
22. The researcher believes that there are other factors that may affect the results of the study and interfere with the whole process of the study, including past or existing physical conditions, treatment or laboratory abnormalities, etc.; or the researcher believes that participating in the study can not maximize the benefits of the patients.
23. Subjects are not suitable to participate in this study for any reason in the judgment of the researcher.

Where this trial is running

Beijing and 4 other locations

• Cancer Hospital Chinese Academy of Medical Sciences — Beijing, China (Recruiting)
• Peking Union Medical College Hospital — Beijing, China (Withdrawn)
• Sun Yat-sen Memorial Hospital, Sun Yat-sen University — Guangzhou, China (Recruiting)
• Henan Provincial Cancer Hospital — Zhengzhou, China (Recruiting)
• Henan Provincial People's Hospital — Zhengzhou, China (Recruiting)

Study contacts

• Principal investigator: Junling Li — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Study coordinator: Junling Li

Conditions Non-Small Cell Lung Cancer; EGFR mutation; Dositinib